Facilitated Poster Session #1: Stream 6 - Type 1 diabetes
Tracks
Meeting Room 101 & 102
| Wednesday, August 19, 2026 |
| 1:00 PM - 1:50 PM |
| Meeting Room 101 & 102 (Level 1) |
Speaker
Prof Timothy Davis
Professor of Medicine
The University of Western Australia
The relationship between serum HDL-cholesterol and all-cause mortality in community-based people with type 1 diabetes: The Fremantle diabetes study Phase I
1:00 PM - 1:06 PMBiography
Prof Davis is Chief Investigator of the landmark Fremantle Diabetes Study, a community-based observational study of diabetes care, control and complications which has been running since 1993.
Prof Timothy Davis
Professor of Medicine
The University of Western Australia
Cardiovascular risk prediction in adults with type 1 diabetes using an equation validated for type 2 diabetes: The Fremantle diabetes study phase II
1:06 PM - 1:12 PMBiography
Prof Davis is Chief Investigator of the landmark Fremantle Diabetes Study which started with Phase I in 1993 and continues through Phase II (recruitment 2008-2011) - these studies have involved around 3,000 participants followed for up to 33 years
Dr Jennifer Snaith
Endocrinologist/ Clinical Researcher
Garvan Institute of Medical Research
Metformin-related reduction in insulin dose requirements in adults with type 1 diabetes is associated with shifts in the gut microbiome
1:12 PM - 1:18 PMBiography
Dr Jennifer Snaith is a St Vincent’s Hospital Staff Specialist Endocrinologist and post-doctoral researcher at the Victor Chang Cardiac Research Institute and the University of New South Wales. She leads type 1 diabetes clinical trials testing the potential for adjunctive therapies to improve cardiometabolic health in type 1 diabetes.
Dr Melissa Lee
Endocrinologist and Senior Clinical Research Fellow
St Vincent’s Hospital
Real-world performance of the Omnipod® 5 automated insulin delivery system in children, adolescents, and adults with Type 1 diabetes in Australia
1:18 PM - 1:24 PMBiography
Melissa H. Lee, MBBS(Hons) FRACP PhD, is an endocrinologist and Senior Clinical Research Fellow at the University of Melbourne and St Vincent’s Hospital. Her research focuses on type 1 diabetes pathophysiology and technology, alongside leading clinical services at Werribee Mercy Hospital and contributing extensively to national diabetes education and research.
Prof Muhammad Yazid Jalaludin
Professor Of Paediatrics
Universiti Malaya
Cost-effectiveness of the MiniMedTM 780G advanced hybrid closed-loop (AHCL) system versus multiple daily injections with self-monitoring blood glucose for managing Type 1 Diabetes in Malaysia
1:24 PM - 1:30 PMBiography
Professor Dr Muhammad Yazid Jalaludin is The Deputy Dean and a Professor of Paediatrics at the Faculty of Medicine, Universiti Malaya. He practices as a Senior Consultant Paediatrician and Senior Consultant Paediatric Endocrinologist at the University Malaya Medical Centre and University Malaya Specialist Centre.
Dr Ella Zomer
Senior Research Fellow
Monash University
Cost-effectiveness of health technologies in adults with type 1 diabetes: an updated systematic review and narrative synthesis
1:30 PM - 1:36 PMBiography
Dr Ella Zomer is a Senior Research Fellow at Monash University. She is the Diabetes and Cardiovascular Disease Program Lead in the Monash University Health Economics Group and Research Lead of the Australian Diabetes Clinical Quality Registry. Her research interest lies in clinical epidemiology and health economics.
Dr Timor Glatzer
Indication Lead
Roche Diabetes Care GmbH
Improving nighttime glucose management by nighttime hypoglycemia prediction
1:36 PM - 1:42 PMBiography
Dr. Timor Glatzer, Clinical Development and Diabetes Indication Lead at Roche Diabetes Care, holds a PhD in immunology following research at the Leibniz Institute and Charité Berlin. He specializes in AI-driven CGM technology, having published extensively on CGM-based diabetes management and innovative digital solutions to improve clinical outcomes for patients.
